A detailed history of Kovack Advisors, Inc. transactions in Kempharm, Inc stock. As of the latest transaction made, Kovack Advisors, Inc. holds 148,802 shares of KMPH stock, worth $735,081. This represents 0.08% of its overall portfolio holdings.

Number of Shares
148,802
Previous 149,532 0.49%
Holding current value
$735,081
Previous $738,000 0.41%
% of portfolio
0.08%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
N/A
-730 Reduced 0.49%
148,802 $735,000
Q2 2024

Aug 02, 2024

BUY
N/A
7,686 Added 5.42%
149,532 $738,000
Q1 2024

Apr 19, 2024

BUY
N/A
445 Added 0.31%
141,846 $700,000
Q4 2023

Feb 02, 2024

BUY
N/A
17,292 Added 13.93%
141,401 $698,000
Q3 2023

Oct 19, 2023

BUY
N/A
2,791 Added 2.3%
124,109 $613,000
Q2 2023

Jul 21, 2023

SELL
$4.94 - $6.29 $7,429 - $9,460
-1,504 Reduced 1.22%
121,318 $599,000
Q1 2023

Apr 20, 2023

BUY
$4.13 - $6.27 $65,576 - $99,555
15,878 Added 14.85%
122,822 $675,000
Q4 2022

Feb 22, 2023

SELL
$4.12 - $5.62 $8,693 - $11,858
-2,110 Reduced 1.93%
106,944 $490,000
Q3 2022

Nov 14, 2022

BUY
$4.5 - $6.85 $103,338 - $157,303
22,964 Added 26.67%
109,054 $680,000
Q2 2022

Aug 10, 2022

SELL
$4.02 - $5.21 $49,172 - $63,728
-12,232 Reduced 12.44%
86,090 $384,000
Q1 2022

May 16, 2022

BUY
$5.0 - $9.26 $50,125 - $92,831
10,025 Added 11.35%
98,322 $494,000
Q4 2021

Jan 18, 2022

BUY
$7.6 - $10.26 $152,281 - $205,579
20,037 Added 29.35%
88,297 $769,000
Q3 2021

Nov 03, 2021

BUY
$8.72 - $13.31 $68,722 - $104,896
7,881 Added 13.05%
68,260 $637,000
Q2 2021

Jul 29, 2021

BUY
$8.52 - $15.47 $514,429 - $934,063
60,379 New
60,379 $774,000

Others Institutions Holding KMPH

About KEMPHARM, INC


  • Ticker KMPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,493,600
  • Market Cap $170M
  • Description
  • KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...
More about KMPH
Track This Portfolio

Track Kovack Advisors, Inc. Portfolio

Follow Kovack Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kovack Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kovack Advisors, Inc. with notifications on news.